Next Article in Journal / Special Issue
Does a Consumer-Targeted Deprescribing Intervention Compromise Patient-Healthcare Provider Trust?
Previous Article in Journal
Assessment of Knowledge, Attitude and Barriers towards Pharmacovigilance among Physicians and Pharmacists of Abbottabad, Pakistan
Previous Article in Special Issue
De-Prescribing of Psychotropic Medications in the Adult Population with Intellectual Disabilities: A Commentary
Article Menu
Issue 2 (June) cover image

Export Article

Open AccessArticle
Pharmacy 2018, 6(2), 30; https://doi.org/10.3390/pharmacy6020030

Benzodiazepines Withdrawal: Initial Outcomes and Long-Term Impact on Falls in a French Nursing Home

1
Maison Hospitalière de Baccarat, 54120 Baccarat, France
2
Service de Pharmacie Clinique, Etablissement Public de Santé Alsace Nord, 67173 Brumath, France
3
Clinique Psychiatrique, Service de Psychiatrie II, Hôpital Civil, CHU de Strasbourg, 67091 Strasbourg, France
4
Equipe de Liaison et de Soins en Addictologie, C.H. Saint Jean de Dieu, 69008 Lyon, France
5
Service Pharmacie, CHU de Strasbourg, Faculté de Pharmacie, EA7396, 67091 Strasbourg, France
*
Author to whom correspondence should be addressed.
Received: 24 February 2018 / Revised: 4 April 2018 / Accepted: 4 April 2018 / Published: 6 April 2018
(This article belongs to the Special Issue Deprescribing)
Full-Text   |   PDF [296 KB, uploaded 3 May 2018]   |  

Abstract

Long-term use of benzodiazepines (BZDs) is known to induce tolerance and dependence, and increase the risk of falls-related injuries in older adults. We present a study carried out in a French nursing home that concerns the implementation of a BZD withdrawal program reassessed at one year. BZD deprescription was achieved by gradual cessation of doses. A secondary benefit of this program was assessed by comparing the number of falls among residents before and after withdrawal. The number of falls was recorded over a six-month period prior to the onset of withdrawal (T1) and then over a six-month period after reassessment at one year (T2). At the beginning, 31 (28.7%) of the patients were under BZD. Total deprescription was obtained for 11 patients. The number of falls per patient over the T1 period was not different between the two groups (future non-withdrawn and withdrawn patients in BZD): 2.1 ± 1.3 and 2.3 ± 0.6 falls per resident, respectively. Conversely, the number of falls per patient was significantly decreased in the population completely withdrawn in BZD between the T1 and T2 periods (2.3 ± 0.6 vs. 0.5 ± 0.2 falls, p = 0.01). The results show that BZD deprescription, through a gradual reduction of doses, is possible to achieve. View Full-Text
Keywords: older patients; benzodiazepine; withdrawal; fall; deprescription older patients; benzodiazepine; withdrawal; fall; deprescription
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Javelot, H.; Marquis, A.; Antoine-Bernard, E.; Grandidier, J.; Weiner, L.; Javelot, T.; Michel, B. Benzodiazepines Withdrawal: Initial Outcomes and Long-Term Impact on Falls in a French Nursing Home. Pharmacy 2018, 6, 30.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Pharmacy EISSN 2226-4787 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top